Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan/HCTZ Long-term Safety in Essential Hypertension
NCT00326768Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telmisartan and hydrochlorothiazide in essential hypertension, sponsored by Boehringer Ingelheim. Primary endpoints: Incidence of adverse events at 52 weeks, Changes in clinical laboratory tests at 52 weeks and 2 more. Started May 2006; status: completed.
02
Drugs
telmisartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00326768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326768.